'Cutting the cable' between CD8+ T and T regulatory cells enhances checkpoint immunotherapy

as well as faculty from Saint John's Cancer Institute in Santa Monica; the University of Alabama at Birmingham; and Massachusetts General Hospital and Harvard Medical School.